These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 23293191)
41. Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological response. Carlsson T; Reichard O; Norkrans G; Bläckberg J; Sangfelt P; Wallmark E; Weiland O J Viral Hepat; 2005 Sep; 12(5):473-80. PubMed ID: 16108761 [TBL] [Abstract][Full Text] [Related]
42. Efficacy of pegylated interferon α-2b and ribavirin in chronic hepatitis C virus (genotypes 1 and 4) infection. Wiśniewska-Ligier M; Pawłowska M; Pilarczyk M; Halota W; Woźniakowska-Gęsicka T J Pediatr Gastroenterol Nutr; 2013 Dec; 57(6):694-9. PubMed ID: 23942001 [TBL] [Abstract][Full Text] [Related]
43. Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin. Bonardi R; Tabone M; Manca A; Pellicano R; Ciancio A; Rizzetto M Biomed Pharmacother; 2011 Jul; 65(4):303-6. PubMed ID: 21723079 [TBL] [Abstract][Full Text] [Related]
44. Retreatment with peg-interferon and ribavirin in patients with chronic hepatitis C virus genotype 2 or 3 infection with prior relapse. Lagging M; Rembeck K; Rauning Buhl M; Christensen P; Dalgard O; Färkkilä M; Hellstrand K; Langeland N; Lindh M; Westin J; Norkrans G Scand J Gastroenterol; 2013 Jul; 48(7):839-47. PubMed ID: 23795661 [TBL] [Abstract][Full Text] [Related]
45. Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype. Itokawa N; Atsukawa M; Tsubota A; Kondo C; Hashimoto S; Fukuda T; Matsushita Y; Kidokoro H; Kobayashi T; Narahara Y; Nakatsuka K; Kanazawa H; Iwakiri K; Sakamoto C J Gastroenterol Hepatol; 2013 Mar; 28(3):443-9. PubMed ID: 23173698 [TBL] [Abstract][Full Text] [Related]
46. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Yu ML; Dai CY; Huang JF; Chiu CF; Yang YH; Hou NJ; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL Hepatology; 2008 Jun; 47(6):1884-93. PubMed ID: 18508296 [TBL] [Abstract][Full Text] [Related]
47. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Manns M; Marcellin P; Poordad F; de Araujo ES; Buti M; Horsmans Y; Janczewska E; Villamil F; Scott J; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M Lancet; 2014 Aug; 384(9941):414-26. PubMed ID: 24907224 [TBL] [Abstract][Full Text] [Related]
48. Sustained virological response based on the week 4 response in hepatitis C virus genotype 1 patients treated with peginterferons α-2a and α-2b, plus ribavirin. Dogan UB; Akin MS; Yalaki S Eur J Gastroenterol Hepatol; 2013 Nov; 25(11):1317-20. PubMed ID: 23680912 [TBL] [Abstract][Full Text] [Related]
49. A European single centre experience of management of hepatitis C virus genotype 4 infection with pegylated-interferon and ribavirin. Selvapatt N; Habibi MS; Brown A J Med Virol; 2015 Oct; 87(10):1716-21. PubMed ID: 25914248 [TBL] [Abstract][Full Text] [Related]
50. Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon-ribavirin combination therapy after 4 weeks of treatment. Orlent H; Desombere I; Hansen B; Van Vlierberghe H; Haagmans B; De Knegt RJ; Schalm SW; Leroux-Roels G; Janssen HL; Eur J Gastroenterol Hepatol; 2010 Dec; 22(12):1443-8. PubMed ID: 21389795 [TBL] [Abstract][Full Text] [Related]
51. Durability of Response in Children Treated With Pegylated Interferon alfa [corrected] 2a ± Ribavirin for Chronic Hepatitis C. Schwarz KB; Molleston JP; Jonas MM; Wen J; Murray KF; Rosenthal P; Gonzalez-Peralta RP; Lobritto SJ; Mogul D; Pavlovic V; Warne C; Wat C; Thompson B J Pediatr Gastroenterol Nutr; 2016 Jan; 62(1):93-6. PubMed ID: 26284539 [TBL] [Abstract][Full Text] [Related]
52. Induction pegylated interferon alfa-2b in combination with ribavirin in patients with genotypes 1 and 4 chronic hepatitis C: a prospective, randomized, multicenter, open-label study. Brady DE; Torres DM; An JW; Ward JA; Lawitz E; Harrison SA Clin Gastroenterol Hepatol; 2010 Jan; 8(1):66-71.e1. PubMed ID: 19747986 [TBL] [Abstract][Full Text] [Related]
53. Outcome of antiviral treatment in patients with chronic genotype 1 HCV hepatitis. A retrospective study in 507 patients. Sporea I; Sirli R; Curescu M; Gheorghe L; Popescu A; Bota S; Iacob S J Gastrointestin Liver Dis; 2010 Sep; 19(3):261-4. PubMed ID: 20922189 [TBL] [Abstract][Full Text] [Related]
54. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. Hézode C; Forestier N; Dusheiko G; Ferenci P; Pol S; Goeser T; Bronowicki JP; Bourlière M; Gharakhanian S; Bengtsson L; McNair L; George S; Kieffer T; Kwong A; Kauffman RS; Alam J; Pawlotsky JM; Zeuzem S; N Engl J Med; 2009 Apr; 360(18):1839-50. PubMed ID: 19403903 [TBL] [Abstract][Full Text] [Related]
55. [HCV Genotype Distribution in Southwest China and Its Influence on Patients' Response to Pegylated-interferon α-2a Plus Ribavirin Therapy]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2015 Jul; 46(4):573-7. PubMed ID: 26480661 [TBL] [Abstract][Full Text] [Related]
56. Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients. Kuboki M; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T J Gastroenterol Hepatol; 2007 May; 22(5):645-52. PubMed ID: 17444850 [TBL] [Abstract][Full Text] [Related]
57. Pegylated interferon alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. Moreno L; Quereda C; Moreno A; Perez-Elías MJ; Antela A; Casado JL; Dronda F; Mateos ML; Bárcena R; Moreno S AIDS; 2004 Jan; 18(1):67-73. PubMed ID: 15090831 [TBL] [Abstract][Full Text] [Related]
58. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. Chung RT; Andersen J; Volberding P; Robbins GK; Liu T; Sherman KE; Peters MG; Koziel MJ; Bhan AK; Alston B; Colquhoun D; Nevin T; Harb G; van der Horst C; N Engl J Med; 2004 Jul; 351(5):451-9. PubMed ID: 15282352 [TBL] [Abstract][Full Text] [Related]
59. Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial. Liu CH; Liu CJ; Huang CF; Lin JW; Dai CY; Liang CC; Huang JF; Hung PH; Tsai HB; Tsai MK; Lee CY; Chen SI; Yang SS; Su TH; Yang HC; Chen PJ; Chen DS; Chuang WL; Yu ML; Kao JH Gut; 2015 Feb; 64(2):303-11. PubMed ID: 24747867 [TBL] [Abstract][Full Text] [Related]
60. ANTIVIRAL TREATMENT OF HEPATITIS C IN SERBIAN PRISON SETTING: MEDICAL TREATMENT OUTCOMES AND PATIENTS' ADHERENCE. Simonović Babić J; Bojović K; Delić D; Katanić N; Mitrović N; Malinić J Med Pregl; 2016; 69(3-4):85-91. PubMed ID: 27506095 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]